Katherine Littrell - Jazz Pharmaceuticals Vice President - Investor Relations
| JAZZ Stock | USD 110.91 0.33 0.30% |
President
Katherine Littrell is Vice President - Investor Relations of Jazz Pharmaceuticals PLC
| Address | Waterloo Exchange, Dublin, Ireland, D04 E5W7 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1216 %, meaning that it created $0.1216 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B).Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Katherine Strei | Emergent Biosolutions | 62 | |
| Filippo Lanzi | Haleon plc | N/A | |
| Bill Aurora | Neurocrine Biosciences | N/A | |
| Atul Saran | Emergent Biosolutions | 51 | |
| Keith Choy | Haleon plc | 55 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Adam Havey | Emergent Biosolutions | 53 | |
| Lisa Paley | Haleon plc | 57 | |
| Michael Smith | PetIQ Inc | 46 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 |
Jazz Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO and Executive VP | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Independent Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, President COO | ||
| Robert MD, Executive Development | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Senior Vice President - Finance, Principal Accounting Officer | ||
| Rene Gal, President COO | ||
| Seamus Mulligan, Director | ||
| Russell Cox, COO and Executive VP | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Executive Officer | ||
| Samantha Pearce, Senior International | ||
| George Eliades, Senior Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, NonExecutive Employee | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive VP and General Counsel | ||
| Patricia Carr, Senior Officer | ||
| Heather McSharry, Independent Director | ||
| Michael Miller, Sr. VP of U.S. Commercial | ||
| Jed MD, Senior Medicine | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Philip Johnson, Executive CFO | ||
| Norbert Riedel, Independent Director | ||
| Catherine Sohn, Independent Director | ||
| Heidi Manna, Executive Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Co-Founder, Executive Chairman and CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 11.08 B | ||||
| Shares Outstanding | 62.35 M | ||||
| Shares Owned By Insiders | 2.81 % | ||||
| Shares Owned By Institutions | 95.80 % | ||||
| Number Of Shares Shorted | 3.26 M | ||||
| Price To Earning | 35.18 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 6.1 | Revenue Per Share 60.581 | Quarterly Revenue Growth 0.041 | Return On Assets 0.0456 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.